IRIS
FICORELLA, Corrado
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.678
AS - Asia 6.667
EU - Europa 6.369
SA - Sud America 879
Continente sconosciuto - Info sul continente non disponibili 297
AF - Africa 107
OC - Oceania 14
Totale 27.011
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.518
SG - Singapore 2.860
IE - Irlanda 1.514
CN - Cina 1.436
RU - Federazione Russa 1.322
TR - Turchia 748
BR - Brasile 744
DE - Germania 702
HK - Hong Kong 636
IT - Italia 575
VN - Vietnam 550
SE - Svezia 548
UA - Ucraina 439
GB - Regno Unito 415
FR - Francia 257
FI - Finlandia 236
IN - India 98
CA - Canada 86
CZ - Repubblica Ceca 79
BD - Bangladesh 64
PL - Polonia 61
JP - Giappone 57
NL - Olanda 57
MX - Messico 47
BE - Belgio 41
AR - Argentina 39
IQ - Iraq 35
ZA - Sudafrica 35
ES - Italia 32
MA - Marocco 23
EC - Ecuador 22
ID - Indonesia 19
CO - Colombia 18
UZ - Uzbekistan 17
AT - Austria 15
VE - Venezuela 15
PY - Paraguay 14
AU - Australia 13
CL - Cile 13
AE - Emirati Arabi Uniti 12
MY - Malesia 12
RO - Romania 12
IL - Israele 11
KR - Corea 11
PK - Pakistan 11
JO - Giordania 10
KE - Kenya 10
PT - Portogallo 10
SA - Arabia Saudita 10
TN - Tunisia 10
AZ - Azerbaigian 8
BG - Bulgaria 8
EU - Europa 8
NP - Nepal 8
PH - Filippine 8
TH - Thailandia 8
EG - Egitto 7
LT - Lituania 7
DZ - Algeria 6
EE - Estonia 6
PE - Perù 6
RS - Serbia 6
BO - Bolivia 5
HN - Honduras 5
CH - Svizzera 4
JM - Giamaica 4
KH - Cambogia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AL - Albania 3
AO - Angola 3
BN - Brunei Darussalam 3
CG - Congo 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HR - Croazia 3
IR - Iran 3
KZ - Kazakistan 3
LY - Libia 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
DM - Dominica 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
LB - Libano 2
MD - Moldavia 2
MN - Mongolia 2
NO - Norvegia 2
OM - Oman 2
PR - Porto Rico 2
PS - Palestinian Territory 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BB - Barbados 1
BF - Burkina Faso 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
Totale 26.700
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.682
Chandler 1.617
Singapore 1.529
Dublin 1.514
San Jose 1.220
Dallas 1.154
Ashburn 728
Hong Kong 624
Santa Clara 559
Boardman 532
Izmir 360
The Dalles 344
Council Bluffs 294
Wilmington 293
Nanjing 280
New York 277
Princeton 240
Lawrence 239
Ann Arbor 235
San Mateo 224
Beijing 217
Moscow 216
Ho Chi Minh City 178
Los Angeles 142
Hanoi 130
Munich 120
Lauterbourg 116
Milan 98
Nanchang 98
Seattle 87
Bremen 77
Brno 75
São Paulo 74
Columbus 68
Helsinki 68
Shenyang 64
Des Moines 59
Woodbridge 58
Dearborn 55
Tianjin 55
Tokyo 54
Verona 51
Frankfurt am Main 50
Warsaw 50
Hefei 49
L'aquila 49
Hebei 44
Amsterdam 43
Rome 42
Orem 41
Brussels 40
London 37
Kunming 36
Dong Ket 34
Brooklyn 33
Jinan 33
Stockholm 33
Atlanta 31
Jiaxing 30
Norwalk 30
Philadelphia 30
Montreal 29
San Francisco 29
Hangzhou 28
Zhengzhou 28
Chicago 26
Falkenstein 26
Denver 25
Johannesburg 25
Guangzhou 23
Houston 23
Shanghai 22
Changsha 21
Phoenix 21
Pune 21
Boston 20
Chennai 20
Da Nang 20
Mountain View 20
Rio de Janeiro 20
Ningbo 18
Poplar 18
Aquila 17
Haiphong 17
Belo Horizonte 16
Brasília 16
Casablanca 16
Toronto 16
Tashkent 15
Falls Church 14
Lappeenranta 14
Manchester 13
Auburn Hills 12
Berlin 12
Fremont 12
Guayaquil 12
L’Aquila 12
Mexico City 12
Nuremberg 12
Redwood City 12
Totale 17.573
Salva come PNG Salva come JPEG
Nome #
Breast cancer and psychological resilience among young women 290
The supportive care task force at the University of L'Aquila: 2-years experience 212
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 199
Emotional Impact of Breast Cancer Treatment: cross-sectional study on level of anxiety, anger, psychological distress and depression in 2-years perspective 185
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 183
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines 176
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. 171
Does pain intensity predict a poor opioid response in cancer patients? 170
Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. 168
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer 167
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 166
Psychological impact of clinical treatment after breast cancer diagnosis in younger patients (38–50 age range): An explorative 3-year observational study 165
Concurrent RAS and RAS/BRAF V600E variants in colorectal cancer: more frequent than expected? 162
P16 hypermethylation contributes to the characterization of gene inactivation profiles in primary gastric cancer 161
"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer 160
Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer 157
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 157
Tapentadol in cancer pain management: a prospective open-label study 151
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting 151
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 151
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 150
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 149
Efficacy and safety of deep, continuous palliative sedation at home: A retrospective, single-institution study 148
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 148
Oncology together for L'Aquila: early resumption of integrated oncological activities after the earthquake 147
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer 145
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 145
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 145
Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay 144
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 144
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 142
Pain evaluation and management: a survey of Italian radiotherapists 141
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 141
Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience 140
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice 140
Predictive Features of Resilience in Early Breast Cancer Young Patients: experience in Real Life 139
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 138
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, Fir-B/FOx, according to seconde-line treatment and KRAS genotype 138
Circulating micrornas as prognostic and therapeutic biomarkers in breast cancer molecular subtypes 138
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 138
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 137
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 137
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 136
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 136
Efficacy of pregabalin in the management of cetuximab-related itch 134
Multimodality treatment in metastatic gastric cancer: From past to next future 134
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 133
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 133
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer 131
What Is Known about Theragnostic Strategies in Colorectal Cancer 131
Evaluation of prognostic factors for survival in transverse colon cancer 131
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer 130
Low morphine doses in opioid-naive cancer patients with pain 130
Meccanismo d’azione e farmacologia di nuovi composti organometallici nel trattamento del carcinoma del colon-retto. 129
Gabapentin in the treatment of severe sweating experienced by advanced cancer patients 129
Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors 129
Poker association of weekly alternating 5-fluorouracil, irinotecan,bevacizumab and oxaliplatin (FIrB/FOx) in first line treatment of metastatic colorectal cancer: a phase II study 128
Integrating oncology and palliative home care in Italy: the experience of the "L'Aquila per la Vita" Home Care Unit 128
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients 128
Knowledge and Attitudes of Young Italian Medical Oncologists Toward the Approach and Treatment of Pain: No Changes, Despite the Law 127
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 127
Assessment and treatment of symptoms among italian medical oncologists 126
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line 126
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 126
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen 126
Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib. 125
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain 125
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 125
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 124
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 124
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 124
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 124
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases 124
Novel P53 mutations detected by FAMA in colorectal cancers 123
Switching from Transdermal Drugs: An Observational "N of 1" Study of Fentanyl and Buprenorphine 123
Prognostic relevance of PIK3CA mutations in breast cancer patients treated with primary dose-dense epirubicin/cyclophosphamide -> dose-dense docetaxel 123
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 123
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 123
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management 123
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 122
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 122
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation 122
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 121
Cerebral metastasis from ovarian cancer treated with a multidisciplinary approach. Case report and review of literature 120
Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy 119
Can malignant bowel obstruction in advanced cancer patients be treated at home ? 119
Survivorship in young women after early breast cancer: a cross-sectional study of emotional traits along 3-years perspective 119
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 119
NEW MUTATIONS AND PROTEIC VARIANTS OF NBS1 ARE IDENTIFIED IN CANCER CELL LINES 118
In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human cancer cells 118
Biological Function of Oncogenic KRAS In Promoting Angiogenesis 118
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice 118
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 117
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 117
Sleep Disturbances in Patients with Advanced Cancer in Different Palliative Care Settings. 116
Choice of chemotherapy schedules in elderly patients (> 75 years) with metastatic colorectal cancer (mcrc) according to comorbidity 116
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 116
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 116
Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen 116
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer 116
Totale 13.842
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.274
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.274
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.276 0 115 223 68 62 24 26 91 85 33 105 444
2022/20234.568 315 300 71 492 444 471 4 298 1.943 21 125 84
2023/20241.080 151 56 49 126 75 297 11 97 2 46 35 135
2024/20254.726 120 87 434 222 641 410 616 349 1.057 219 335 236
2025/20268.755 426 926 686 1.124 904 706 1.463 313 748 912 449 98
2026/2027220 206 14 0 0 0 0 0 0 0 0 0 0
Totale 27.011